12:00 AM
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IFN-alpha kinoid: Completed Phase I/II enrollment

Neovacs completed enrollment of 28 patients in the double-blind, placebo-controlled, dose-escalation, European Phase I/II IFN-K-001 trial evaluating intramuscular IFN-K over 3 months. Data...

Read the full 93 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >